Raimund H M Preidl Tobias Ebker Martin Raithel Falk Wehrhan Friedrich W Neukam Philipp Stockmann
10.1186/1471-230X-14-6
BMC Gastroenterol
2014 Jan 8;14:6.
CC BY
https://pubmed.ncbi.nlm.nih.gov/24400722/
Anti-Inflammatory Agents / adverse effects Antibodies, Monoclonal, Humanized / adverse effects Bisphosphonate-Associated Osteonecrosis of the Jaw / etiology Bone Density Conservation Agents / adverse effects Crohn Disease / drug therapy Diphosphonates / adverse effects
Anti-Inflammatory Agents / adverse effects Antibodies, Monoclonal, Humanized / adverse effects Bisphosphonate-Associated Osteonecrosis of the Jaw / etiology Bone Density Conservation Agents / adverse effects Crohn Disease / drug therapy Diphosphonates / adverse effects Case Reports Research Support, Non-U.S. Gov't Adalimumab Adult Female Humans Osteonecrosis / drug therapy Anti-Inflammatory Agents Antibodies, Monoclonal, Humanized Bone Density Conservation Agents Diphosphonates Adalimumab
PMC3890650
24400722
Osteonecrosis of the jaw in a Crohn's disease patient following a course of Bisphosphonate and Adalimumab therapy: a case report
2014